Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
Prof. James F. Howard, Prof. Saiju Jacob and Nancy Law will be participating in an #AANAM Industry Therapeutic Update, Journey to the cause to discuss rare diseases, like #myastheniagravis and share the patient perspective. Tune in through our virtual boo
— UCB News (@ucb_news) 20.04.2021 -
Our aim for the #ImmunologySummit2021 is to change clinical practice by harnessing the transformative power of #technology and #learning from other medical specialities and industries to bring better patient outcomes. https://t.co/7GeRb5dNWx
— UCB News (@ucb_news) 20.04.2021 -
Through our participation at #AANAM, we will share the unique experiences of those living with #myastheniagravis (MG). While there is no cure for MG, we are dedicated to making the balancing act between living with rare diseases and treatment more managea
— UCB News (@ucb_news) 19.04.2021
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
